Data from University College London (UCL) Hospitals NHS Foundation Trust Update Knowledge in Mantle Cell Lymphoma (Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat...).

A new report from the University College London (UCL) Hospitals NHS Foundation Trust provides real-world data on the use of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory mantle cell lymphoma (MCL) in the United Kingdom. The study found that brexu-cel demonstrated impressive responses in patients who had failed previous treatments, with an overall response rate of 93% and a complete response rate of 67%. However, the analysis also highlighted a significant dropout rate due to disease progression and manufacturing issues, and non-relapse mortality events were a concern. Overall, the outcomes for patients in the UK were comparable to those seen in clinical trials and other real-world reports. [Extracted from the article]